NASDAQ
Adaptive Biotechnologies Corporation (ADPT)
♥ 540 Thanks from members
Adaptive Biotechnologies Corporation (ADPT) exhibits a polarized market profile, balancing strong revenue growth and clinical adoption of its clonoSEQ MRD franchise against persistent net losses, debt-related pressures, and a valuation near analyst price targets.